Abstract
Biologic drugs, such as ustekinumab, have significantly transformed psoriasis treatment. Ustekinumab targets the shared interleukin (IL)-12/23p40 subunit, preventing IL-23 from binding to its receptor and blocking translocation of Signal Transducer and Activator of Transcription 3 (STAT3). Although ustekinumab is highly effective, clinical response is variable and there is an unmet need for the identification of biomarkers predictive of response. Here we monitor IL-23-induced STAT3 activation in peripheral blood mononuclear cells (PBMCs) to identify predictive biomarkers of outcome to ustekinumab.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
